This document includes Supplementary Information

(Supplementary Table 1 & Supplementary Figures 1-5) to:

Genetic and phenotypic diversity of fecal *Candida albicans* strains in Irritable Bowel Syndrome

Isabelle A.M. van Thiel^{1,2}, Aimilia Stavrou^{3,4}, Auke de Jong^{3,5}, Bart Theelen³, Mark Davids^{6,7}, Theodorus B.M. Hakvoort^{1,2,7} Iris Admiraal-van den Berg^{1,2,7}, Isabelle C.M. Weert¹, Martine A.M. Hesselink-van de Kruijs⁸, Duong Vu³, Christine Moissl-Eichinger⁹, Sigrid E.M. Heinsbroek^{1,2,10}, Daisy M.A.E. Jonkers⁸, Ferry Hagen^{3,5} Teun Boekhout^{3,4}, Wouter J. de Jonge^{1,2,10,11}, René M. van den Wijngaard^{1,2,10,*}

- 1. Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centers, location AMC. Amsterdam, The Netherlands.
- 2. Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, location AMC. Amsterdam, The Netherlands.
- 3. Westerdijk Fungal Biodiversity Institute. Utrecht, The Netherlands.
- 4. Institute of Biodiversity and Ecosystem Dynamics (IBED), University of Amsterdam. Amsterdam, The Netherlands.
- 5. Department of Medical Microbiology, University Medical Center Utrecht. Utrecht, The Netherlands.
- 6. Laboratory of Experimental Vascular Medicine, Amsterdam University Medical Centers, location AMC. Amsterdam, The Netherlands.
- 7. Microbiota Center Amsterdam, Amsterdam University Medical Centers, location AMC. Amsterdam, The Netherlands.
- 8. Division Gastroenterology-Hepatology, Department of Internal Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+. Maastricht, The Netherlands.
- 9. Diagnostic and Research Institute of Hygiene, Microbiology and Environmental Medicine, Center for Microbiome Research, Medical University Graz. Graz, Austria.
- 10. Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, location AMC. Amsterdam, The Netherlands.
- 11. Department of General, Visceral, Thoracic and Vascular Surgery, University Hospital Bonn. Bonn, Germany.

Supplementary Table 1.

Primer sequences for quantitative PCR experiments.

Gene of interest	Identifier	Forward/Reverse	Primer sequences (5'-3')			
TDH3 XM 714816 1		Forward	CGGTCCATCCCACAAGGA			
reference	$ M_{14810.1} $	Reverse	AGTGGAAGATGGGATAATGTTACCA			
PMA1	XM_712666.2	Forward	TTGCTTATGATAATGCTCCATACGA			
reference		Reverse	TACCCCACAATCTTGGCAAGT			
ALC1	XM_712984.2	Forward	CAACAGGCACCTCAGCATCTAC			
ALSI		Reverse	CTCCACCAGTAACAGATCCACTAGTAA			
A L C 2	XM_705343.2	Forward	CAACTTGGGTTATTGAAACAAAAACA			
ALS3		Reverse	AGAAACAGAAACCCAAGAACAACCT			
NDCI	XM_710106.1	Forward	ACATGTGAAGCCCGTTTTGC			
INKGI		Reverse	CTGTGTTGTTGTCTGTTGCGT			
UCC1	XM_713897.2	Forward	GTCAGCTTCCTGCACCTCAT			
HGCI		Reverse	TTGGTGGTGGTGGTTGCATA			
CAD2	XM_705955.2	Forward	CCAATGAAGCCGGTGGTAGT			
SAP2		Reverse	TATTTGTCCCGTGGCAGCAT			
CAD4	XM_712961.1	Forward	GCCGATGGTTCTGTTGCAC			
SAP4		Reverse	ACACCACCAATACCAACGGT			
ECE1	XM_706502.1	Forward	CCATCATCCACCATGCTCCA			
		Reverse	ACAGTAGGTGCTTGGTCAGC			
CDD 1	XM_718116.2	Forward	CCATGACTCCTGCTACCGTG			
CDRI		Reverse	CCATCGAGACCAACCCAACA			
MDD 1	XXA 714072.2	Forward	ACAATTTGGCCACCCCTGAA			
MDKI	AWI_/140/2.2	Reverse	CCAACACGGAACTACCCCAA			



)	5	Observed		Shannon		Faith's PD	
		F value	P value	F value	P value	F value	P value
	Time_Point	2.359	0.159	2.33	0.161	1.19	0.304
	Treatment	0.323	0.584	13.061	0.006	0.222	0.648
	Effect	0.485	0.504	0.031	0.865	0.089	0.772
	Time_Point:Treatment	0.001	0.979	0.003	0.958	0.702	0.424
	Time_Point:Effect	0.343	0.573	0.854	0.38	0.425	0.531
	Treatment:Effect	1.169	0.308	0.6	0.458	0.234	0.64
	Time_Point:Treatment:Effect	1.215	0.299	8.013	0.02	0.04	0.847

Supplementary Figure 1. Mycobiota composition as expressed by Shannon index associates with probiotic treatment and outcome, although no community-based associated was determined. a-b) Alpha diversity as expressed by observed species, Shannon index, and Faith's Phylogenetic Distance of mycobiota samples. Shannon index is significantly different for allocated treatment. Results linear mixed effect models presented in b). c) Mycobiota composition, displayed in a multilevel principle component analysis, is not significantly different after treatment.







b		Observed		Shannon		Faith's PD	
		F value	P value	F value	P value	F value	P value
	Time_Point	0.045	0.835	0.014	0.906	0.681	0.425
	Treatment	4.674	0.052	0.451	0.515	2.412	0.146
	Effect	7.312	0.019	2.001	0.183	7.87	0.016
	Time_Point:Treatment	0.103	0.754	5.958	0.031	1.131	0.309
	Time_Point:Effect	0.619	0.447	0.5	0.493	3.59	0.082
	Treatment:Effect	2.928	0.113	2.357	0.151	2.542	0.137
	Time_Point:Treatment:Effect	0.143	0.712	0.058	0.813	1.479	0.247

Supplementary Figure 3. Bacterial microbiome composition is associated with treatment allocation to a limited extent. a-b) Alpha diversity metrics (Observed species, Shannon index, Faith's Phylogenetic distance) as shown for both outcome (improver/non-improver) and allocated treatment (placebo/probiotic). Shannon diversity generally associates with allocated treatment (p=0.031, Linear Mixed Effect Models (LME). Results linear mixed effects model presented in b). c) Community analysis by multilevel PCA based on Bray-Curtis dissimilarities. Symbol color represents allocated treatment. Composition is associated with treatment (p=0.007, PERMANOVA).



Supplementary Figure 4. MixOmics loading plot indicates shift of Verrucomicrobia.

Loading plot indicating separation of microbial taxa along principal components (PC) 1 and PC2. Verrucomicrobia locate in the upper-left quadrant while greatest separation for other taxa is seen along PC1.



Supplementary Figure 5. Archaeal reads show high inter-individual variability. Archaeal reads counts displayed on genus level. Each column represents one paired sample. Each separated segment indicates individual species. Reads are highly variable between and within patients.